Segment Data

6 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Data

Segment Data

The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Prior to its spin-off on April 1, 2022, the Company reported the Diabetes Care business as an organizational unit within the Medical segment. As such, historical financial information of the Medical segment has been recast in the tables below to reflect the total segment revenues and revenues from continuing operations. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. See Note 2 for further information.

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended March 31,
(Millions of dollars)	2023						2022
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	616	$	454	$	1,070	$	590	$	460	$	1,049
Medication Management Solutions	550		173		723		461		143		604
Pharmaceutical Systems (a)	173		394		567		125		375		501
Total segment revenues	$	1,339	$	1,022	$	2,360	$	1,176	$	978	$	2,154
Life Sciences
Integrated Diagnostic Solutions	$	422	$	466	$	888	$	618	$	532	$	1,150
Biosciences	159		228		386		129		206		335
Total segment revenues	$	581	$	694	$	1,275	$	747	$	738	$	1,485
Interventional
Surgery	$	295	$	86	$	381	$	268	$	72	$	340
Peripheral Intervention	256		213		468		240		210		450
Urology and Critical Care	263		74		336		239		82		320
Total segment revenues	$	813	$	373	$	1,186	$	746	$	364	$	1,111
Total revenues from continuing operations	$	2,733	$	2,088	$	4,821	$	2,669	$	2,081	$	4,750

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

	Six Months Ended March 31,
(Millions of dollars)	2023						2022
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	1,235	$	873	$	2,109	$	1,210	$	936	$	2,146
Medication Management Solutions	1,114		316		1,430		945		286		1,231
Pharmaceutical Systems (a)	292		684		976		228		669		897
Total segment revenues	$	2,642	$	1,873	$	4,515	$	2,383	$	1,892	$	4,274
Life Sciences
Integrated Diagnostic Solutions	$	930	$	911	$	1,841	$	1,232	$	1,062	$	2,295
Biosciences	296		440		736		258		416		674
Total segment revenues	$	1,226	$	1,351	$	2,577	$	1,490	$	1,478	$	2,968
Interventional
Surgery	$	582	$	162	$	744	$	549	$	152	$	701
Peripheral Intervention	492		410		902		457		407		863
Urology and Critical Care	522		148		670		492		168		661
Total segment revenues	$	1,595	$	720	$	2,315	$	1,498	$	727	$	2,225
Total Company revenues from continuing operations	$	5,462	$	3,944	$	9,407	$	5,372	$	4,096	$	9,468

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Segment income for the three and six-month periods was as follows:

	Three Months Ended March 31,				Six Months Ended March 31,
(Millions of dollars)	2023		2022		2023		2022
Income from Continuing Operations Before Income Taxes
Medical (a)	$	641	$	476	$	1,195	$	1,048
Life Sciences	394		475		827		1,009
Interventional	297		280		598		544
Total Segment Operating Income	1,333		1,231		2,621		2,602
Acquisition-related integration and restructuring expense	(62)		(28)		(106)		(62)
Net interest expense	(108)		(95)		(204)		(191)
Other unallocated items (b)	(635)		(665)		(1,301)		(1,307)
Total Income from Continuing Operations Before Income Taxes	$	529	$	442	$	1,009	$	1,041

(a)The amounts for the three and six months ended March 31, 2022 include a charge of $54 million recorded to Cost of products sold to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit, as well as a charge of $35 million to adjust estimated future product remediation costs.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.